U.S. Markets close in 2 hrs 53 mins

Imprimis Pharmaceuticals, Inc. (IMMY)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.5492+0.03 (+0.83%)
As of 12:57PM EDT. Market open.
People also watch
OCRXDPRXEVOKINNLHTBX

Imprimis Pharmaceuticals, Inc.

12264 El Camino Real
Suite 350
San Diego, CA 92130
United States
858-704-4040
http://www.imprimispharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees141

Key Executives

NameTitlePayExercisedAge
Mr. Mark L. Baum J.D.Founder, Chief Exec. Officer and Director536.03kN/A44
Mr. Andrew R. Boll CFA, CMAChief Financial Officer and Corp. Sec.326.21kN/A35
Mr. John P. Saharek MBAChief Commercial Officer358.46kN/A57
Mr. Clayton D. Edwards R.Ph., MBAChief Operating OfficerN/AN/A49
Mr. David MoufarrègeVP of TechnologyN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Imprimis Pharmaceuticals, Inc. engages in the development, production, and sale of medications to physicians and patients in the United States. Its ophthalmology program consists of Dropless Therapy injectable and LessDrops topical formulations. The company also offers a conscious sedation medication, the IV Free MKO Melt, an alternative to intravenous sedation. It focuses on providing ophthalmology programs and medications for glaucoma, wet age-related macular degeneration, diabetic macular edema, and chronic dry eye disease. The company’s medicine business includes medications used in several therapeutic areas, including oncology, autoimmunity, chronic infectious diseases, and endocrine and metabolic diseases; and urology business comprises a series of injectable erectile dysfunction formulations for patients that are refractory to or are otherwise unable to take phosphodiesterase type 5 inhibitors, such as sildenafil, tadalafil, and vardenafil. In addition, it develops PPS-DR (pentosan polysulfate sodium delayed-release) formulations as alternatives to Elmiron for patients diagnosed with interstitial cystitis; and develops and sells therapeutic alternatives to Daraprim, Thiola, and Calcium Disodium Versenate. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.

Corporate Governance

Imprimis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.